Search clinical trials for: HLX208

Total 205 results

Shanghai Henlius Biotech

Recruiting

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Non Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Squamous Non-small-cell Lung Cancer

China
Shanghai Henlius Biotech

Not yet recruiting

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Shanghai Henlius Biotech

Unknown

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Henlius Biotech

Recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

Brain Tumor, Primary

China
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation

NSCLC

China
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

ESCC or Esophageal Adenosquamous Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Hepatocellular Carcinoma

China
Shanghai Henlius Biotech

Not yet recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation

Solid Tumor
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Advanced Melanoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Shanghai Henlius Biotech

Completed

Mass Balance Study of [14C]HLX208 in China Healthy Subjects

Mass Balance Study in Healthy Subjects

China
Shanghai Henlius Biotech

Active, not recruiting

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Head and Neck Squamous Cell Carcinoma

China
Shanghai Henlius Biotech

Recruiting

Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma by AJCC V8 Stage

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Anaplastic Thyroid Cancer | ATC

China
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

Langerhans Cell Histiocytosis | Erdheim-Chester Disease | LCH | ECD

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

Metastatic Colorectal Cancer | mCRC

China
Shanghai Henlius Biotech

Recruiting

HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Shanghai Henlius Biotech

Withdrawn

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Hepatocellular Carcinoma (HCC)

China
Shanghai Henlius Biotech

Completed

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Advanced Solid Tumors

Australia
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

China
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

CRC

China
Tianjin Medical University Cancer Institute and...

Recruiting

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Advanced Hepatocellular Carcinoma

China
Taizhou Hanzhong biomedical co. LTD

Not yet recruiting

Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)

Anaplastic Thyroid Cancer

China
Shanghai Henlius Biotech

Not yet recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Small-cell Lung Cancer

China
Shanghai Zhongshan Hospital
Shanghai Henlius Biotech

Not yet recruiting

Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Shanghai Henlius Biotech

Not yet recruiting

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Carcinoma, Hepatocellular
Shandong University

Recruiting

Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer

Cervical Cancer

China
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Suspended

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC

Colorectal Cancer Metastatic

China
Zhejiang Cancer Hospital

Recruiting

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

Extensive Stage Lung Small Cell Cancer

China
Shanghai Henlius Biotech

Recruiting

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

Non-small Cell Lung Cancer | Locally Advanced or Metastatic Solid Tumors

Australia
Shanghai Henlius Biotech

Completed

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

Adult Solid Tumor

China
Shanghai Henlius Biotech

Withdrawn

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Advanced Solid Tumor

United States
Taizhou Hanzhong biomedical co. LTD

Recruiting

Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Cancer

China
Taizhou Hanzhong biomedical co. LTD

Unknown

A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
Shanghai Henlius Biotech

Active, not recruiting

A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma

Solid Tumor and Lymphoma

China
Taizhou Hanzhong biomedical co. LTD

Unknown

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Melanoma

China
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Taizhou HoudeAoke Biomedical Co., Ltd.

Unknown

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Melanoma

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumors

China
Fudan University

Recruiting

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)

Treatment Efficacy

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
Shanghai Henlius Biotech

Completed

A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

B-cell Lymphomas
Shanghai Henlius Biotech

Completed

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Rheumatoid Arthritis
Shanghai Henlius Biotech

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression

HLX07, nsqNSCLC, High EGFR Expression

China
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

MSI-H Solid Malignant Tumor

China

3

Subscribe